Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Mesna, you must consult a qualified healthcare professional.
| 100 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 55150-520 |
| 100 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 63323-733 |
| 100 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 25021-201 |
| 400 mg/1 | TABLET, FILM COATED | ORAL | 50742-354 |
Detailed information about Mesna
Mesna is a specialized chemoprotective agent used primarily to prevent hemorrhagic cystitis (severe bladder bleeding) in patients receiving ifosfamide or high-dose cyclophosphamide chemotherapy.
Dosage for Mesna is strictly calculated based on the dose of the chemotherapy (ifosfamide) being administered. The goal is to maintain a protective concentration of Mesna in the bladder for the duration of acrolein excretion.
The standard IV regimen involves giving Mesna in three doses equal to 20% of the ifosfamide dose (w/w).
For example, if a patient receives 1000 mg of ifosfamide, they would receive 200 mg of Mesna at 0, 4, and 8 hours.
Because oral Mesna is less bioavailable than IV, the doses are larger. The standard regimen is:
Mesna is approved for use in children. The dosing logic remains the same as in adults, with the dose tied directly to the ifosfamide or cyclophosphamide dose (calculated by body surface area in mg/m²). Clinical studies have shown that children may clear Mesna more rapidly than adults, so pediatric oncologists may occasionally use more frequent dosing or continuous infusions to ensure adequate bladder protection.
Since Mesna is cleared almost entirely by the kidneys, one might expect dose reductions. However, because the goal is to have the drug present in the urine, dose reductions are rarely performed unless the patient's kidney function is so poor that they cannot produce enough urine to flush the bladder. In such cases, the chemotherapy itself is usually contraindicated.
No specific dose adjustments are provided for patients with liver disease, as the liver plays a minimal role in the metabolism and excretion of Mesna.
In geriatric patients, the primary concern is underlying renal insufficiency. While the Mesna dose isn't typically adjusted, the ifosfamide dose often is, which naturally results in a lower Mesna dose.
Timing is the most critical factor in Mesna therapy. If a dose is missed, the bladder is left unprotected against the toxic metabolites of chemotherapy. If you miss a dose at home, call your oncology team immediately. They may instruct you to take it right away or come into the clinic for an IV rescue dose. Never double the next dose to catch up.
There is no specific antidote for Mesna overdose. Symptoms of an overdose may include nausea, diarrhea, abdominal pain, and headache. Because Mesna is rapidly cleared by the kidneys, supportive care and hydration are the primary treatments. In clinical trials, doses up to 70 mg/kg were given without significant toxic effects, but any suspected overdose should be treated as a medical emergency.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose without medical guidance. The success of your chemotherapy and the safety of your bladder depend on strict adherence to the Mesna schedule.
Because Mesna is always given in combination with powerful chemotherapy agents, it can be difficult to distinguish which side effects are caused by Mesna and which are caused by the cancer treatment. However, the following have been identified as common reactions specifically associated with Mesna protocols:
Mesna is a vital component of certain chemotherapy regimens, but it carries specific risks that must be managed by an experienced oncology team. The most important safety consideration is that Mesna only protects the bladder. It does not prevent other side effects of chemotherapy, such as hair loss, nausea, or low blood cell counts. Furthermore, Mesna does not prevent hemorrhagic cystitis in 100% of patients; therefore, regular monitoring of the urine for blood remains necessary.
No FDA black box warnings for Mesna.
There are no absolute drug-drug contraindications where Mesna must never be used with another systemic medication. However, there are in vitro (in the IV bag) incompatibilities. Mesna should not be mixed in the same IV line or bag with:
Mesna is contraindicated in patients with a known hypersensitivity to Mesna or any other thiol compound.
Relative contraindications require a careful risk-benefit analysis by the oncology team:
Mesna is classified as FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.
It is not known whether Mesna or its metabolite dimesna is excreted in human milk. However, because the drugs Mesna is paired with (ifosfamide and cyclophosphamide) are excreted in breast milk and are highly toxic to infants,
Mesna is a thiol compound that serves as a regional detoxifying agent. Its primary molecular target is acrolein, a toxic unsaturated aldehyde produced during the hepatic metabolism of oxazaphosphorine chemotherapy (ifosfamide and cyclophosphamide).
In the systemic circulation, Mesna is rapidly oxidized to the chemically stable and inactive disulfide, dimesna. This is a crucial 'safety switch' that prevents Mesna from reacting with the chemotherapy in the blood, which would reduce the drug's ability to kill cancer cells. Upon reaching the kidneys, dimesna is filtered and then actively reabsorbed into the renal tubular cells. Inside these cells, it is reduced back into the active thiol form (Mesna) by glutathione reductase and then secreted back into the urine. In the bladder, the free thiol group of Mesna reacts with the electrophilic double bond of acrolein via a Michael addition reaction. This creates a stable, water-soluble, and non-toxic thioether (4-hydroxy-ethyl-sulfonate) that is excreted in the urine.
The pharmacodynamic effect of Mesna is strictly local to the urinary tract. It does not have systemic effects on blood pressure, heart rate, or the central nervous system at therapeutic doses. The duration of effect is short, directly mimicking the transit time of urine from the kidney to the bladder. Continuous protection requires the presence of Mesna in the urine for as long as acrolein is being generated (usually 8-12 hours after a bolus of chemotherapy).
Common questions about Mesna
Mesna is primarily used as a protective agent to prevent a serious condition called hemorrhagic cystitis, which involves severe inflammation and bleeding of the bladder. This condition is a common and dangerous side effect of certain chemotherapy drugs, specifically ifosfamide and high-dose cyclophosphamide. When these chemotherapy drugs are broken down by the body, they produce a toxic byproduct called acrolein that collects in the bladder and damages its lining. Mesna works by chemically neutralizing acrolein in the bladder, turning it into a harmless substance that can be urinated out. It is an essential 'add-on' medication that allows patients to receive life-saving chemotherapy with a much lower risk of permanent bladder damage.
The most common side effects of Mesna include nausea, vomiting, diarrhea, and a bad taste in the mouth, often described as a sulfur-like or 'rotten egg' flavor. Many patients also report feeling very tired, having a headache, or experiencing a temporary flushing of the skin. Because Mesna is always given with chemotherapy, it can be difficult to tell which drug is causing these symptoms, but the sulfur taste and nausea are frequently linked to Mesna itself. Most of these side effects are temporary and resolve once the treatment cycle is finished. However, you should always report any new symptoms to your oncology team to ensure they are managed correctly.
While there is no known direct chemical interaction between Mesna and alcohol, it is generally recommended that you avoid alcohol during your chemotherapy treatment. Alcohol can cause dehydration, which is counterproductive when you are taking Mesna, as the drug requires plenty of fluids to help flush the bladder effectively. Additionally, alcohol can worsen the nausea, dizziness, and fatigue that often accompany chemotherapy and Mesna. To ensure your body is in the best possible condition to handle the treatment, sticking to water and clear fluids is the safest choice. Always consult your oncologist before consuming any alcohol during your treatment window.
Mesna is classified as a Category B medication, meaning it is generally considered low-risk based on animal studies, but there is limited data on its safety in pregnant humans. However, Mesna is almost always used with ifosfamide, which is known to be very harmful to a developing fetus. If chemotherapy is necessary to save the mother's life during pregnancy, Mesna is typically used because the benefit of preventing a maternal bladder hemorrhage is considered more important than the theoretical risks of the drug. Breastfeeding is not recommended while taking Mesna because the accompanying chemotherapy drugs can pass into breast milk and harm the baby. Any decision regarding Mesna during pregnancy must be made through a detailed discussion between you and your medical team.
Mesna begins working almost immediately after it is administered intravenously, as it quickly reaches the kidneys and bladder to begin neutralizing toxins. When taken in tablet form, it takes about 1 to 4 hours to reach peak protective levels in the urinary tract. This is why the timing of the doses is so strict; the first dose is usually given at the exact same time as the chemotherapy to ensure protection is present from the very start. The drug does not stay in the system for long, which is why multiple doses are required throughout the day to keep the bladder protected as the chemotherapy continues to be processed by your body. If the timing is off, the bladder could be exposed to toxins for several hours.
No, you should never stop taking Mesna or skip a dose unless your doctor specifically tells you to do so, usually because of a severe allergic reaction. Mesna is timed to match the 'danger window' when chemotherapy toxins are passing through your bladder. If you stop taking it too early, those toxins will no longer be neutralized, and you could develop severe bladder inflammation and bleeding within hours or days. Even if you are feeling well or experiencing mild side effects like nausea, finishing the full prescribed course of Mesna is vital for your safety. If you are having trouble keeping the pills down due to vomiting, call your doctor immediately so they can give you the drug through an IV instead.
If you miss a dose of Mesna, you must contact your oncology clinic or doctor immediately. Timing is the most critical part of this treatment, and even a delay of a few hours can leave your bladder vulnerable to damage from the chemotherapy. Your doctor may tell you to take the missed dose right away, or they may ask you to come into the clinic for an emergency intravenous dose to ensure your bladder is protected. Do not simply wait for the next dose and do not double the dose to catch up. Keep the phone number for your oncology 'on-call' nurse handy at all times while you are taking this medication at home.
Mesna is not known to cause weight gain. It is a short-acting drug used for only a few days at a time during chemotherapy cycles, and it does not affect your metabolism or appetite in a way that would lead to increased weight. In fact, many patients experience temporary weight loss during treatment due to side effects like nausea or a reduced appetite caused by the chemotherapy. If you notice sudden weight gain or swelling (edema) in your legs or ankles, you should report this to your doctor. This is more likely to be a sign of fluid retention related to your heart or kidney function, or perhaps a side effect of other medications like steroids, rather than the Mesna itself.
Mesna can be taken with most other systemic medications, but it has some specific 'incompatibility' issues. For example, it should not be mixed in the same IV bag or line with certain other chemotherapy drugs like cisplatin, as they can neutralize each other before they even enter your body. It can also cause a false-positive result on urine tests for ketones, which is important for people with diabetes to know. There are also rare reports of Mesna affecting the way blood thinners like warfarin work. Because of these potential issues, you must provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are taking before you start treatment.
Yes, Mesna is available as a generic medication in both its injectable and oral tablet forms. The brand name for Mesna in the United States is Mesnex, but many hospitals and clinics use the generic version, which is chemically identical and provides the same level of bladder protection. Generic availability has made this essential protective treatment more affordable and widely accessible for cancer patients. Whether you receive the brand name or the generic, the dosing and safety precautions remain exactly the same. Your insurance provider or the hospital pharmacy will typically determine which version is used for your treatment.
Other drugs with the same active ingredient (Mesna)
> Warning: Stop taking Mesna and call your doctor immediately if you experience any of these symptoms. These may indicate a severe allergic reaction or a dermatological emergency.
Mesna is typically used for short durations (the length of a chemotherapy cycle). There is very little evidence suggesting long-term cumulative toxicity from Mesna itself. The primary concern with long-term use is the potential for developing a sensitivity or allergy to the drug over repeated exposures. Some patients with autoimmune disorders (like Lupus or Rheumatoid Arthritis) may be at a higher risk for developing delayed hypersensitivity reactions after multiple cycles of Mesna.
No FDA black box warnings are currently issued for Mesna. However, the FDA does emphasize the critical warning regarding hypersensitivity reactions. Because Mesna is a thiol compound, it can trigger severe immune responses in susceptible individuals. Clinicians are advised to monitor patients closely during the first few doses and to be prepared for emergency resuscitation if an allergic reaction occurs.
Report any unusual symptoms to your healthcare provider. Even minor symptoms like a mild rash can be a precursor to a more serious reaction during the next dose.
Patients receiving Mesna must be monitored closely to ensure the drug is providing adequate protection:
Mesna may cause dizziness or somnolence (excessive sleepiness) in some patients. Because it is given alongside chemotherapy, which also causes significant fatigue, patients are generally advised not to drive or operate heavy machinery until they know how the medication affects them. Most patients will require a driver to take them home from chemotherapy sessions.
There is no direct chemical interaction between Mesna and alcohol. However, alcohol can contribute to dehydration and may worsen the nausea and dizziness associated with chemotherapy. Patients are generally advised to avoid alcohol during their treatment cycles to ensure optimal hydration and to minimize stress on the liver and kidneys.
Mesna should not be discontinued prematurely. If the Mesna schedule is stopped while chemotherapy metabolites are still being excreted, the risk of severe bladder bleeding increases significantly. Discontinuation is only warranted if a severe allergic reaction occurs, in which case the oncology team will immediately pivot to alternative protective strategies or stop the chemotherapy altogether.
> Important: Discuss all your medical conditions with your healthcare provider before starting Mesna. Provide a full list of your allergies, especially to sulfur-containing drugs or other thiol compounds.
There are few moderate systemic drug interactions because Mesna is so rapidly cleared and stays primarily in the blood and urinary tract. However, medications that significantly alter renal blood flow (like high-dose NSAIDs) could theoretically affect the delivery of Mesna to the bladder, though this is not a common clinical concern.
There is limited data on herbal interactions with Mesna. However, patients should be cautious with:
This is a critical area for Mesna.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Keep a list of everything you take, including over-the-counter vitamins, to share with your oncology pharmacist.
Patients should be screened for cross-sensitivity to other thiol-containing medications. These include:
If you have had a reaction to any of these drugs, you must inform your oncologist before receiving Mesna.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Mesna. In some cases, the risk of severe bladder bleeding from chemotherapy may outweigh a mild allergy risk, but this is a complex medical decision.
Mesna is widely used in pediatric oncology. The safety and effectiveness have been established in children, and the dosing is adjusted based on the chemotherapy dose.
Clinical studies of Mesna did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
While Mesna is cleared renally, the goal is to get the drug into the urine. Therefore, standard doses are typically used even in mild-to-moderate renal impairment. In severe renal impairment (GFR < 30 mL/min), the risk of ifosfamide toxicity is so high that the entire treatment plan is usually altered. There is no specific data on Mesna clearance during hemodialysis, but its small molecular weight suggests it would be dialyzable.
No studies have been conducted in patients with hepatic impairment. However, since the liver is not the primary organ of metabolism or excretion for Mesna, liver disease is not expected to significantly alter the drug's safety or efficacy.
> Important: Special populations require individualized medical assessment. Your oncology team will tailor the Mesna protocol based on your age, organ function, and the specific demands of your cancer treatment.
| Parameter | Value |
|---|---|
| Bioavailability | 45% - 58% (Oral) |
| Protein Binding | 60% - 75% |
| Half-life (Mesna) | 22 minutes |
| Half-life (Dimesna) | 70 minutes |
| Tmax (Oral) | 1.5 to 4 hours |
| Metabolism | Rapid oxidation to Dimesna (blood); Reduction to Mesna (kidney) |
| Excretion | Renal (>90%) |
Mesna is classified as a Uroprotective Agent. It is the only drug in this specific class, though other drugs like amifostine serve similar 'chemoprotective' roles for different organs (like the salivary glands or kidneys).